Search results
-
Dr Daniel Hodson
... to characterise how new therapeutic agents that are entering trials for lymphoma may exert some of their effect though changes in ...
-
Professor Tim Eisen
... AstraZeneca, where I am currently responsible for oncology trials from first in man to Phase II. ...
-
Dr Elena Provenzano
... My primary interest is the translational aspect of clinical trials particularly in the neoadjuvant setting. Current trials include ARTemis, PARTNER, PRIMETIME and Neo-RT clinical trials in ...
-
Dr Finian Leeper
... properties and a close relative obatoclax is in clinical trials for multiple cancers. (b) synthesis of thiamin diphosphate (TPP) ...
-
Dr Gaia Schiavon
... biomarkers and study designs in ‘window of opportunity’ trials - Identification of newer imaging criteria for response assessment to ... RECIST’s limitations - Pharmacodynamics in clinical trials, disease linkage data to guide indication selection and targeted patient ...
-
Dr George Follows
... post, and I am developing a translational science / clinical trials interest. I am the clinical lead for CLL and lymphoma in Cambridge, and chair the Haematology Clinical Trials team. I am a committee member of the Cambridge Clinical Cancer Trials ...
-
Professor Grant Stewart
... a focus on developing and promoting surgery related clinical trials and translational research. Grant has a specific interest in optimising ... Stewart has developed a range of interlinked clinical trials and translational research which are all underpinned by clinical ...
-
Dr Helen Morris
... and collaborated on a number of randomised controlled trials and other well-designed studies in the field of cancer and genetics in a ...
-
Dr Helen Hatcher
... lead investigator in several multicentre and international trials. ...
-
Dr Kelly Holmes
... setting up and co-ordinating the work for clinical research trials with the aim of developing novel imaging techniques in patients with ...
-
Dr Ali Amin Al Olama
My research has focused on discovery of genetic risk factors of prostate cancer through genome-wide association studies and fine-mapping. I am a core member of an international consortium PRACTICAL (Prostate Cancer Association Group to Investigate...
-
Dr Andreas Bender
Previously affiliated with the Lead Discovery Informatics (LDI) group of Novartis in Cambridge/MA, I am now developing and applying cheminformatics techniques in the drug discovery field in my group with the University of Cambridge. Our expertise ranges...
-
Dr Alejandra Bruna
We aimed to study the effects of the TGF-beta pathway in breast cancer stem cell (BCSC) regulation. To define a role of the TGF-beta pathway in the regulation of human BCSCs, we have analyzed a panel of breast cancer cell lines that represent the...
-
Professor Antonis Antoniou
My main research interest is the development and application of statistical modelling techniques for addressing clinical questions, and the development of risk prediction tools which are used in clinical practice. ...
-
Dr Catherine Lindon
My lab studies cell division in human cells, with particular focus on regulation by ubiquitin-mediated proteolysis. We use time-lapse fluorescence imaging of live cells to measure proteolysis of substrates in real time, and to study the role of...
-
Dr Alison Dunning
Work in the Centre for Cancer Genetic Epidemiology "wet lab" involves running very high throughput SNP-chip genotyping and Next Generation Sequencing (NGS) studies. We search for genetic risk factors for both cancer susceptibility and treatment-response...
-
Dr Ashray Gunjur
I am an early-career medical oncologist from Melbourne, Australia. I am broadly interested in immuno-oncology and the link between cancer and the gut microbiome, and am undertaking a PhD supervised by Dr David Adams and Dr Trevor Lawley (Wellcome...
-
Dr Ahsan MEMON
Ahsan has developed a sui generis versatile holographic system capable of diverse photo-perturbation techniques including photo-manipulation, photo-activation, photo-ablation, optical-trapping and optogenetics, combined with multi-modal imaging...
-
Dr Aisling Redmond
Aisling received her undergraduate degree in Genetics from Trinity College Dublin and PhD from Dublin City University. She completed postdoctoral fellowships in the breast cancer field at the Royal College of Surgeons in Ireland and Cancer Research UK...
-
Professor Alan Warren
Our long-term goal is to elucidate the molecular mechanisms of ribosome assembly in eukaryotic cells and to understand how defects in this process cause bone marrow failure and cancer predisposition. Assembly of the two subunits of the ribosome,...
-
Dr Anna Piskorz
... focus on translational research in high grade serous ovarian cancer (HGSOC). I work on identification of genomic biomarkers that ...
-
Dr Bristi Basu
I co-lead the Cambridge Experimental Cancer Medicine Centre with Prof Duncan Jodrell and the CRUK Cambridge Centre Pancreatic Cancer Programme with Dr Giulia Biffi. Other roles include Capacity Building leadership team within the Cambridge NIHR...
-
Dr Daniel Barnes
... These individuals are at increased risk of breast cancer and ovarian cancer in women, and breast cancer and prostate cancer in men. I am ...
-
Professor Steve Charnock-Jones
... underlying the progression from endometriosis to clear cell ovarian cancer. Endometriosis is a relatively common condition affecting ... of these cases there is an increased incidence of clear cell ovarian cancer. Recent work has shown that mutations in Arid1a gene are ...
-
Professor Evis Sala
Now based in Rome, my research in Cambridge focused on integrated diagnostics, through the clinical development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging...
-
Dr Geoff Macintyre
... associated with treatment resistance in high-grade serous ovarian cancer (HGSOC). These methods are developed using whole-genome ...
-
Dr Honglin Song
I am working on genetic susceptibility to the risk of ovarian cancer and clinical outcome after a diagnosis of ovarian cancer. I have led the work of the group in common/rare gene variation ...
-
Professor James Brenton
... clinical trials with sequential collection and profiling of ovarian cancer tissues before and during therapy. Array-based expression ...
-
Miss Alicia Gonzalez Diaz
-
Mr Arman Ghodsinia
-
Professor Tony Green
Tony Green is Professor of Haemato-oncology in the University of Cambridge and honorary Consultant Haematologist at Addenbrookes Hospital. He was appointed Head of the University Department of Haematology (2000-2020), and in 2016 was appointed Director...
-
Mr Asif Jah
Mr Asif Jah ...
-
Professor Bertie Gottgens
The Göttgens group uses a combination of experimental and computational approaches to study how transcription factor networks control the function of blood stem cells and how mutations that perturb such networks cause leukaemia. This integrated approach...
-
Dr Cedric Ghevaert
Cedric Gevaert graduated from the medical school of the University Libre de Bruxelles in 1997 and subsequently became a fellow of the Royal College of Physicians, London (2000). He specialised in Haematology and became a fellow of the Royal College of...
-
Dr David Adams
... Consortium and aims to generate phenotyping data for over 200 genetically modified mouse lines per year to gain a better understanding of ...
-
Dr Danish Mazhar
Dr Mazhar was a Medical Undergraduate at the University of Oxford and completed his Clinical Training in London. He undertook Specialist Training in Medical Oncology at the Hammersmith and Charing Cross Hospitals in London. He was awarded a PhD by...
